Avedro announced that four new providers—Providence Health Plan in the Pacific Northwest, Health New England, HealthPartners Minnesota, and Public Employees Health Plan (PEHP) in Utah—have issued positive coverage policies for Avedro’s FDA-approved corneal cross-linking procedure, bringing the total number of commercial plans covering the KXL system and its associated Photrexa drug formulations to over 65. These three plans bring the total number of covered lives in the United States to more than 180 million.
In addition, Avedro has secured positive coverage from the United States’ largest national commercial payers, including United Healthcare, Anthem Blue Cross Blue Shield, Aetna, Cigna, Humana, and HealthNet. The company estimates that more than 95% of commercially covered lives have access to the Avedro’s potentially sight-saving technology.
“We are very pleased to see that in just 1 year, access has rapidly and dramatically improved for patients needing therapeutic treatment for progressive keratoconus,” Reza Zadno, PhD, Chief Executive Officer of Avedro, said in a company news release. “In addition to securing coverage from our country’s top commercial payers, we’ve received a unique J-code from CMS. This is in large part due to the amazing support and hard work of the societies, doctors and patient advocacy groups who see and hear from patients daily. Avedro will continue to invest in reimbursement services to ensure corneal cross-linking is accessible to patients struggling with progressive keratoconus.”
Patients can find the list of private payer insurance companies providing coverage for corneal cross-linking at LivingwithKeratoconus.com.